Lilly's Kisunla gains approval in China
Eli Lilly (NYSE: LLY) has announced that China’s National Medical Products Administration has approved Kisunla (donanemab-azbt) for certain adults with early Alzheimer’s disease.
The nod marks a significant milestone as China becomes the fourth major market to greenlight the drug after the USA, Japan, and the UK. Nearly 6% of people over 65 in the country are estimated to be living with Alzheimer’s, a figure expected to rise to 11% by 2050.
The Phase III TRAILBLAZER-ALZ 2 study formed the basis for Kisunla’s approval. Patients who were less advanced in the disease experienced the greatest benefit, with a 35% slower decline in cognitive and functional measures compared to placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze